# R&D AI Strategy 2026

**Record owner:** R&D Digital Office
**Approver:** R&D AI Steering Committee
**Status:** Version 1.0, approved
**Effective or as-of date:** 1 January 2026
**Review cycle:** Annual

## Purpose

ACME Pharma R&D wants to use AI to improve research productivity without weakening research integrity, confidentiality, intellectual property protection, or regulatory readiness. The strategy covers the ten activities recorded as UC-RD-001 through UC-RD-010, including proposed, on-hold, and unofficial activity that is not approved for routine use.

## Strategic objectives

1. Reduce the time required to summarize scientific publications and internal research notes.
2. Improve consistency of experiment planning by making prior assumptions, constraints, and open questions visible.
3. Support early hypothesis generation while keeping final research decisions with accountable scientists.
4. Protect confidential research data, trade secrets, unpublished results, and collaboration know-how.
5. Create a reusable governance pattern for future AI-enabled R&D use cases.

## Boundaries

The AI system may assist with search, summarization, classification, drafting, and comparison. It must not independently approve research direction, replace scientific peer review, approve regulatory claims, or decide whether a candidate moves to the next development phase.

The strategy assumes a phased rollout. Pilot use cases may run in a controlled sandbox using approved data sets. Any production use must pass security, legal, privacy, validation, and R&D governance review.

## Key decisions still open

- Whether external model providers may process unpublished research text.
- Whether any research data may be used for model training, fine-tuning, or vendor product improvement.
- Whether co-developed models or prompts are owned by the company, the vendor, or jointly.
- Whether cloud-hosted model endpoints satisfy R&D confidentiality and data residency expectations.
- How model outputs will be captured in research records when they influence decisions.

## ACME Pharma R&D operating context

ACME Pharma is a 50,000-employee global life-sciences company with a central R&D organization of roughly 9,000 employees and long-running partnerships with universities, contract research organizations, technology providers, and data vendors. The R&D AI program sits inside the R&D Digital Office, but its users span discovery biology, translational medicine, preclinical safety, clinical pharmacology, biomarker science, regulatory science, and scientific knowledge management.

This strategy covers pre-approval R&D use cases, not commercial, manufacturing, or patient-facing medical advice. The highest-risk boundary is where AI output starts to influence a GxP-relevant decision, regulatory submission support, or an electronic research record later relied on for development decisions.

## AI use-case portfolio

| Use case | Activity | Current boundary |
|---|---|---|
| UC-RD-001 | Public literature triage | Operational; source-linked summaries |
| UC-RD-002 | Internal research-note summarization | Controlled pilot in an approved workspace |
| UC-RD-003 | Experiment-design challenge | Controlled development; advisory; GxP boundary pending |
| UC-RD-004 | Candidate prioritization | Controlled pilot; advisory and not a gate decision |
| UC-RD-005 | Lab-note synthesis | On hold; original records may not be replaced |
| UC-RD-006 | Patent landscape support | Controlled development with Legal/IP restrictions |
| UC-RD-007 | Regulatory response outline drafting | Proposed only; no drafting, regulatory, or submission use approved |
| UC-RD-008 | Biomarker-study feasibility summarization | Proposed; no system assigned |
| UC-RD-009 | Supplier literature-monitoring feed | Operational within approved public and internal watchlist data |
| UC-RD-010 | Research meeting preparation assistant | Unofficial shadow use; not an approved service |

## Governance decision points

The strategy requires a documented decision whenever a use case moves from public information to internal research data, from sandbox to routine use, from advisory output to decision support, or from non-GxP exploration to GxP-relevant evidence. Each transition requires evidence of data classification, intended use, human accountability, supplier restrictions, validation or assurance approach, and records-management expectations.

## Governance dependency added after inventory review

The strategy now requires the R&D Digital Office to maintain both an AI use-case inventory and an AI system inventory. Strategy approval is not enough to expand a pilot; the relevant use case and supporting system must both show owner, intended use, data class, supplier involvement, GxP boundary, lifecycle state, and monitoring expectations.

## 2026 implementation assumptions

The R&D AI strategy assumes that the first twelve months will remain a controlled adoption period. The Digital Office is expected to provide a common intake route, but scientific functions are still allowed to propose local use cases where the data, decision impact, and supplier footprint are documented before testing starts. This creates a deliberate tension: researchers want quick access to tools that remove manual literature and note-review work, while Quality, Legal/IP, Privacy, and Security expect evidence before any tool touches confidential material.

For planning purposes, the strategy separates three decision levels. Level 1 covers productivity support using public literature or training examples. Level 2 covers internal research material where outputs may influence study design, candidate prioritization, or portfolio discussion. Level 3 covers GxP-adjacent or submission-support activities where outputs could become part of an electronic record, validation package, regulatory response, or inspection-relevant rationale. The strategy says Level 3 is not prohibited, but it requires a documented intended-use statement, accountable process owner, quality review, traceability to source evidence, and a validation or computer software assurance rationale.

## Portfolio pressure points observed by the R&D AI Steering Committee

The strategy notes three pressure points that are likely to matter in governance review. First, individual teams are already using public AI assistants for literature summaries because approved internal tools are slower and less flexible. Second, several external research collaborations include AI-enabled analysis work even though the AI component is not always visible in the contract summary. Third, the difference between a research aid and a decision-support tool is not stable: a tool may begin as a drafting assistant, but its output can become influential once it appears in governance decks, candidate review packets, or study design notes.
